Pharsight

Drugs that contain Sildenafil Citrate

1. Liqrev patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11337979 CMP DEV LLC Liquid oral formulations for sildenafil
Dec, 2038

(15 years from now)

US11464778 CMP DEV LLC Liquid oral formulations for sildenafil
Dec, 2038

(15 years from now)

Market Authorisation Date: 28 April, 2023

Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening

Dosage: SUSPENSION;ORAL

More Information on Dosage

LIQREV family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic